Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.44 |
| ▸ | PDE5A | O76074 | 1/20 | 0.44 |
| ▸ | PDE6A | P16499 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 10/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.40 |
| ▸ | CASR | P41180 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4155138 | 0.89 | CASR (0.52) | PDE10APDE5APDE6APDE4AHTR7 | |
| SCHEMBL4143434 | 0.87 | TP53 (0.44) | TP53PTGDR2POLBMTHFD2CASR | |
| SCHEMBL4135630 | 0.82 | C5AR1 (0.50) | TP53POLB | |
| SCHEMBL13851592 | 0.81 | TP53 (0.50) | TP53POLBCASR | |
| SCHEMBL4135003 | 0.81 | P2RX3 (0.46) | TP53POLBCASRP2RX3 | |
| SCHEMBL4151564 | 0.78 | CASR (0.50) | MTHFD2CASR | |
| SCHEMBL4142349 | 0.78 | TP53 (0.51) | TP53POLBCASR | |
| SCHEMBL5189813 | 0.77 | CASR (0.56) | MTHFD2CASR | |
| SCHEMBL4143019 | 0.77 | TP53 (0.49) | TP53POLBCASR | |
| SCHEMBL4143059 | 0.77 | TP53 (0.49) | HTR7TP53CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | disclosed |
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | disclosed |
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | disclosed |
| WO-2007062370-A2 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137557-A1 | Calcilytic Compounds | CALCR, SOST, CALCB | PDE10A 754/4885PDE5A 1828/4885PDE6A 2117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.